|Drug Development Plans|
New drugs undergo two types of testing. Initially, preclinical trials test whether a new drug is effective and safe in test tubes and in animals. Then, once preclinical trials indicate safety, clinical trials test the new drug in people. Clinical trials are normally divided into three phases. In Phase I, a few people are tested primarily for potential side effects. In Phases II and III, more people are tested to determine whether the drug is an effective treatment for the intended conditions and to continue monitoring side effects.
As a research-based biotechnology firm, we expect to enter into licensing agreements with pharmaceutical companies for manufacturing and marketing. We do not anticipate undertaking manufacturing and licensing ourselves. Depending on humanitarian and scientific considerations, we may enter into licensing agreements for parts or all of preclinical and clinical trials as well. We are committed to making all of our drugs accessible to the people who need them. This includes undertaking the necessary steps for the drugs to reach the market in a timely manner.
Often, we would like to conduct initial research and pilot tests ourselves. Although each disease is different, for many of the diseases amenable to this treatment technology, $50,000 would fund initial production, purification, and testing of a drug targeted at that disease. If you are interested in learning more about our treatments for immune system diseases, or in supporting or hastening our progress on a particular disease, please Contact Us or visit Support Our Research.
To facilitate the development process and to better achieve our goals, we have filed for patent protection on the design of our immune-modifying drugs.
If you are interested in forming a strategic alliance to support the development of any of the immune system drugs in our pipeline, please click here: For Pharmaceutical Companies.
© 1997-2008 Institute for Applied Biomedicine. All Rights Reserved. Legal Notices.